ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702
United States

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Terrence W. NorchiChairman, Pres, CEO, Sec. & Director552.5kN/A1965
Mr. Richard E. DavisCFO & Treasurer406.25kN/A1958
Dr. Avtar S. DhillonBus. Advisor152kN/A1961
Mr. Rutledge Ellis-BehnkeCo-Founder & Scientific AdvisorN/AN/AN/A
Dr. Steven A. Kates Ph.D.VP of TechnologyN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Corporate Governance

Arch Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.